Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising R&D Activity in the Pharmaceutical Sector
4.2.2 Escalation in the Biologics Market
4.2.3 Government Support for Proteomics and Genomics Research
4.3 Market Restraints
4.3.1 Stringent Regulation
4.3.2 Growing Competition Among the Vendors
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Reagents and Kits
5.1.1.1 Cell-Free Expression
5.1.1.2 Bacterial Expression
5.1.1.3 Yeast Expression
5.1.1.4 Algal Expression
5.1.1.5 Insect Expression
5.1.1.6 Mammalian Expression
5.1.1.7 Other Expression Systems
5.1.2 Service
5.1.3 Others
5.2 By Application
5.2.1 Therapeutic
5.2.2 Industrial
5.2.3 Research
5.3 By End-User
5.3.1 Academia
5.3.2 Biotechnology
5.3.3 Pharmaceuticals
5.4 Geography
5.4.1 North America
5.4.1.1 United states
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies
6.1.2 Bio-Rad Laboratories Inc.
6.1.3 Merck KGaA
6.1.4 New England Biolabs, Inc.
6.1.5 Oxford Expression
6.1.6 Promega Corporation
6.1.7 Qiagen N.V
6.1.8 Takara Bio, Inc.
6.1.9 Thermo Fisher Scientific Inc.


7 MARKET OPPORTUNITIES AND FUTURE TRENDS